- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06802029
PUER ("Risques émergents auparavant non reconnus") Étude clinique de vie (PUER) chez les 6 à 18 ans
Une étude d'observation prospective et non randomisée et multicentrique pour établir un profil de base physique pour les sujets d'étude individuels utilisant diverses modalités et identifier les écarts via une surveillance longitudinale des participants âgés de 6 à 18 ans
The goal of this observational study is to learn about changes in health in children that develop over time that may impact overall health and a healthy lifespan. The main questions it aims to answer are:
- What are the changes in health that impact overall health and lifespan in children; and
- What test(s) are best at finding changes in health in children?
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The two parts of the PUER Research study include (1) Baseline health assessment and (2) blood tests including genetic, molecular, and laboratory profiling. The Baseline assessment will consist of a health history questionnaire interview. Genetic assessment will be conducted using peripheral blood samples. Molecular and laboratory assessments will be conducted using peripheral blood samples and, potentially, urine, stool, and/or saliva samples.
The study will result in cross-sectional and longitudinal real world data collection to inform if any tests used can inform of health changes for individuals and may predict long-term health outcomes. Researchers at study sites will not be blinded to the data being collected during this study.
Type d'étude
Contacts et emplacements
Lieux d'étude
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30350
- Puer Research, LLC
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Male or non-pregnant female; age 6 to less than 18.
La description
Inclusion Criteria:
To participate in the study, patients must meet the following criteria:
-
Male or non-pregnant female; age 6 to less than 18.
-
Females of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at all visits.
-
Presence of
- At least one pathogenic genetic variant in a biological parent, which is annotated as pathogenic in at least one public database, such as dbSNP, ClinVar, VEP (variant effect predictor), etc.; OR
- Presence of unexplained disease, illness, trait, or phenotype.
-
Approval is at the sole discretion of the sponsor.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from study participation:
- Unwillingness or inability to participate in the study.
- Unwillingness or inability to provide assent as per inclusion criterion #1, including those who lack the capacity to provide assent and will obtain 18 years of age prior to completion of the study.
- WOCBP a with positive pregnancy test at enrollment or at any visit.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_ONLY
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
New deviations: 12 months
Délai: 12 months
|
The number of new deviations from a study subject's baseline profile 12 months after enrollment that were previously not known at time of enrollment. |
12 months
|
|
New deviations: 6 months
Délai: 6 months
|
The number of new deviations, not known at the time of enrollment, at 6 months after enrollment. |
6 months
|
|
New deviations: 18 months
Délai: 18 months
|
The number of new deviations, not known at the time of enrollment, at 18 months after enrollment. |
18 months
|
|
New deviations: 24 months
Délai: 24 months
|
The number of new deviations, not known at the time of enrollment, at 24 months after enrollment. |
24 months
|
|
New deviations: 36 months
Délai: 36 months
|
The number of new deviations, not known at the time of enrollment, at 36 months after enrollment. |
36 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Medications
Délai: 6 months, 12 months, 18 months, 24 months, and 36 months after enrollment.
|
The number and change in the number of medications taken by an individual at 6 months, 12 months, 18 months, 24 months, and 36 months after enrollment. |
6 months, 12 months, 18 months, 24 months, and 36 months after enrollment.
|
|
Dietary supplements
Délai: 6 months, 12 months, 18 months, 24 months, and 36 months after enrollment.
|
The number and change in the number of dietary supplements taken by an individual at 6 months, 12 months, 18 months, 24 months, and 36 months after enrollment. |
6 months, 12 months, 18 months, 24 months, and 36 months after enrollment.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Szilard Voros, MD, Principal Investigator
Publications et liens utiles
Publications générales
- Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, Murray ML, Tokita MJ, Gallego CJ, Kim DS, Bennett JT, Crosslin DR, Ranchalis J, Jones KL, Rosenthal EA, Jarvik ER, Itsara A, Turner EH, Herman DS, Schleit J, Burt A, Jamal SM, Abrudan JL, Johnson AD, Conlin LK, Dulik MC, Santani A, Metterville DR, Kelly M, Foreman AK, Lee K, Taylor KD, Guo X, Crooks K, Kiedrowski LA, Raffel LJ, Gordon O, Machini K, Desnick RJ, Biesecker LG, Lubitz SA, Mulchandani S, Cooper GM, Joffe S, Richards CS, Yang Y, Rotter JI, Rich SS, O'Donnell CJ, Berg JS, Spinner NB, Evans JP, Fullerton SM, Leppig KA, Bennett RL, Bird T, Sybert VP, Grady WM, Tabor HK, Kim JH, Bamshad MJ, Wilfond B, Motulsky AG, Scott CR, Pritchard CC, Walsh TD, Burke W, Raskind WH, Byers P, Hisama FM, Rehm H, Nickerson DA, Jarvik GP. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res. 2015 Mar;25(3):305-15. doi: 10.1101/gr.183483.114. Epub 2015 Jan 30.
- Bromberg Y. Building a genome analysis pipeline to predict disease risk and prevent disease. J Mol Biol. 2013 Nov 1;425(21):3993-4005. doi: 10.1016/j.jmb.2013.07.038. Epub 2013 Aug 5.
- Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, Kim JH, Rosenthal EA, Kim DS; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project; Tabor HK, Bamshad MJ, Motulsky AG, Scott CR, Pritchard CC, Walsh T, Burke W, Raskind WH, Byers P, Hisama FM, Nickerson DA, Jarvik GP. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet. 2013 Oct 3;93(4):631-40. doi: 10.1016/j.ajhg.2013.08.006. Epub 2013 Sep 19.
- Han X, Aslanian A, Yates JR 3rd. Mass spectrometry for proteomics. Curr Opin Chem Biol. 2008 Oct;12(5):483-90. doi: 10.1016/j.cbpa.2008.07.024.
- Scaria V. Personal genomes, participatory genomics and the anonymity-privacy conundrum. J Genet. 2014 Dec;93(3):917-20. doi: 10.1007/s12041-014-0451-3. No abstract available.
- Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015 Apr 30;520(7549):609-11. doi: 10.1038/520609a. No abstract available.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- PLI002
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .